Methods and kits useful for diagnosis of urogenital cancer
The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.
1. A method for concentrating and purifying at least one target analyte from a clinical biological sample, comprising the steps of
(a) combining the clinical biological sample with a first aqueous two-phase system (ATPS) composition comprising a polymer and a salt component dissolved in an aqueous solution to form a target-rich phase solution and a target-poor phase solution, such that the target analyte is concentrated in the target-rich phase solution, wherein the polymer comprises 5-60% PEG with a molecular weight of at least 400, and the salt component comprises 0.1-6% K 2 HPO 4 and 0.1-18% KH 2 PO 4 ;
(b) collecting the target-rich phase solution;
(c) adding the target-rich phase solution to a second ATPS composition comprising a second polymer and a second salt component dissolved in an aqueous solution to form a second target-rich phase solution and a second target-poor phase solution, such that the target analyte is concentrated in the second target-rich phase solution, and collecting the second target-rich phase solution, wherein the second polymer comprises 2-25% PEG with a molecular weight of 200 or less, and the second salt component comprises 0.1-50% K 2 HPO 4 and 4-40% KH 2 PO 4 ;
(d) optionally mixing the second target-rich phase from step (c) with a binding buffer to form a mixed solution;
(e) contacting the second target-rich phase from step (c) or the mixed solution from step (d) with a solid phase medium configured to selectively bind the target analyte such that the solid phase medium binds to the target analyte; and
(f) eluting and collecting the target analyte from the solid phase medium with an eluting solution, resulting in a final solution containing the concentrated and purified target analyte;
(g) subjecting said final solution to a diagnostic assay for detection and quantification of the target analyte;
wherein the clinical biological sample is urine;
wherein the target analyte is a biomarker indicating the presence or risk of a medical condition or disease in a patient, wherein the medical condition or disease is urogenital cancer.
2. The method of claim 1 , further comprising the step of washing the solid phase medium with one or more solvents to remove impurities after step (e) and before step (f).
3. The method of claim 1 , further comprising the step of treating the clinical biological sample with a lysing composition before step (a).
4. The method of claim 1 , wherein the binding buffer comprises a chaotropic agent comprising an anion selected from the group consisting of thiocyanate, isothiocyanate, perchlorate, acetate, trichloroacetate, trifluoroacetate, chloride, and iodide.
5. The method of claim 1 , wherein the target analyte is urogenital cfDNA or ctDNA.
6. The method of claim 1 , wherein the target analyte is bladder cancer DNA and the urogenital cancer is bladder cancer.
7. The method of claim 1 , wherein step (e) comprises the following steps:
(i) contacting a portion of the mixed solution with the solid phase medium such that the target analyte binds to the solid phase medium to form a solid phase extraction complex;
(ii) perturbing the solid phase extraction complex and discarding the flow-through; and
(iii) optionally repeating steps (i) and (ii).
8. The method of claim 7 , wherein the solid phase medium is a plurality of beads, wherein the beads are selected from the group consisting of magnetic beads, silica-based beads, carboxyl beads, hydroxyl beads, and amine-coated beads; the solid phase extraction complex is a beads-analyte complex;
perturbing is spinning; and the flowthrough is the supernatant; and
wherein
the target analyte is a nucleic acid less than a target size;
the plurality of beads binds to the target analyte and to other nucleic acids;
the eluting solution is a fractionation buffer that, when contacted with the beads during the elution step (f), causes the target analyte to be released while not releasing the other nucleic acids, resulting in a final solution containing the concentrated and purified target analyte(s); wherein the fractionation buffer comprises a polymer, a chaotropic agent, or any combination thereof.
9. The method of claim 1 ,
wherein the solid phase medium is an extraction column, wherein the extraction column is a spin column; and
wherein step (e) comprises the following steps:
(i) loading a portion of the mixed solution from step (d) onto the extraction column;
(ii) centrifuging the extraction column and discarding the flow-through; and
(iii) optionally repeating steps (i) and (ii) above one or more times, until all of the mixed solution has been passed through the extraction column.
10. The method of claim 1 , further comprising the step of analyzing the final solution from step (f) using ELISA, nucleic acid sequencing, or a PCR-based assay.
11. The method of claim 1 , wherein the clinical biological sample is a bulk fluid sample having a volume >10 mL, further comprising the following step before step (a): dividing the bulk fluid sample into at least two aliquots of a sample solution;
wherein each aliquot is separately combined with the first ATPS in steps (a) and optionally the collected target-rich phase solution from step (b) is separately combined with the second ATPS in step (c) to form each aliquot's second target-rich phase solution; wherein each aliquot's target-rich phase solution from step (b) or each aliquot's second target-rich phase solution from step (c) is combined together to form a final target rich phase solution for step (d).
12. A method of diagnosing or treating urogenital cancer in a patient in need thereof, comprising
(i) obtaining a clinical biological sample from the patient, wherein the clinical biological sample is urine;
(ii) concentrating and purifying at least one target analyte from the clinical biological sample according to the method of claim 1 ;
(iii) analyzing the final solution; and
(iv) determining if the information obtained from the target analyte indicates that the patient has urogenital cancer or is at risk of developing urogenital cancer; and
(v) optionally treating the patient.
13. The method of claim 12 , wherein the target analyte is urogenital cfDNA or ctDNA.
14. The method of claim 12 , wherein the target analyte is bladder cancer DNA and the urogenital cancer is bladder cancer.